Bloodstream Infections
10
3
3
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
10.0%
1 terminated out of 10 trials
85.7%
-0.8% vs benchmark
20%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
INfectious DIsease REgistry BIObank
Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections
ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT
Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study
Clinical Impact of Rapid Identification of Positive Blood Cultures vs. Internal Laboratory Standard
RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI
Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response
Treating Non-typhoidal Salmonella Bloodstream Infections in Children Under Five in DR Congo: a Cohort Study
Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.